Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ETBX 021

Next Previous
X
Search
Drug Profile

ETBX 021

Alternative Names: Ad5 [E1-, E2b-]-HER2/neu Vaccine; ETBX-021

Latest Information Update: 31 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Etubics Corporation
  • Developer NantBioScience
  • Class Cancer vaccines; DNA vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 28 Jan 2020 No recent reports of development identified for phase-I development in Breast-cancer(Late-stage disease, Metastatic disease) in USA (Parenteral, Suspension)
  • 23 Aug 2019 NantCell withdraws the phase Ib/II QUILT-3.044 trial prior to enrolment for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) as the trial was not initiated (NCT03169738)
  • 23 Aug 2019 NantCell withdraws the phase Ib/II QUILT-3.050 trial prior to enrolment for Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Recurrent) as the trial was not initiated (NCT03169777)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top